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ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE
SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY
Ellegard B1, Meyer J1, Caliendo G1, Herdman M2, Romera B3
1The Mount Sinai Medical Center, New York, NY, USA; 23D Health
Research, Barcelona, Barcelona, Spain; 33D Health Research,
Barcelona, Spain
OBJECTIVES: To investigate the economic impact of a device
for automating the preparation of sterile solutions in the Mount
Sinai Hospital Pharmacy. METHODS: The Gri-ﬁll system (G-S)
uses sterile ﬁltration and a documented ﬁlter integrity test for
each unit of sterile solution prepared. The present study exam-
ined the economic impact of the G-S in preparing 3 pain 
management solutions and 4 total parenteral nutrition (TPN)
solutions. Costs were categorized in terms of staff time, drug,
and disposable costs for the G-S versus the usual manual process.
For each product type, a minimum of 30 units were prepared
using each process. Material costs were calculated using Average
Wholesale Prices (AWP) of drugs and disposables; staff costs
were based on hospital administrative costs for pharmacist and
technician time. RESULTS: The number of units prepared for
each solution ranged from 24 to 129. Batch size was consider-
ably larger with the G-S (mean of 30.7 units per batch with G-
S, 4.9 units with the manual system). Production cost per unit
was lower with the G-S for 5 of the 7 solutions studied. Main
differences between the two systems were in terms of disposable
costs, which were proportionally greater with the G-S (mean of
$9.54 per unit with G-S compared to $6.05 manual, for all solu-
tions), and staff costs, which were less with the G-S (mean of
$0.82 per unit compared to $3.84 for the manual system, all
solutions). CONCLUSIONS: The G-S produced cost savings for
most of the solutions studied. The size of savings is dependent
primarily on solution mix and batch size.
PHP4
ECONOMIC COMPARISON OF TWO XENETIX® 300
PRESENTATIONS
Castelli C1, Lamarsalle L2,Vainchtock A2,Woessmer B3
1Institut Universitaire de Recherche Clinique Laboratoire
Epidemiologie et Biostatistique, Montpellier cedex 05, France; 2IMS
Health—GYD institut, Lyon, France; 3GUERBET, Roissy CDG Cedex,
France
OBJECTIVES: Two approaches are available for contrast agent
injection in Multislice CT: single-patient (SiPA) and multi-patient
(MuPA): The former requires one set of devices for 1 patient, the
latter uses one set for two to four patients. The objective is to
quantify the beneﬁt in terms of time and cost saving between the
two approaches. METHODS: The study was performed in two
Spanish hospitals. Assessment was based on three measurements:
time spent carrying out the injection, quantity of devices used,
volumes of XENETIX® ﬁlling the syringe and injected to
patients. The costs of devices and XENETIX® were taken from
hospital bills. Times collected were linked to costs through an
average hourly cost of nurses and/or radiodiagnostic specialists
involved. A sensitivity analysis was performed to determine in
which proportions of 2-, 3-, or 4-patient vials the MuPA is dom-
inant. RESULTS: 209 patients were included in two groups. The
durations of manipulation are favourable to the MuPA (121 vs.
151sec/patient) but patients were not identically distributed: the
ﬁrst patients’ durations in the MuPA are higher than the later
ones. So a sensitivity analysis was performed by varying the pro-
portion of vials with 2,3,4 patients. These simulations reveal that
the MuPA is dominant in nearly all cases (except when the rate
of patients treated with a 2-patient vial is superior to 20%, which
is not realistic). In a sample of 200 patients the SiPA and the
MuPA entails mean total costs of €11,972 and €10,931 respec-
tively (p < 0.0001 Wald-test) with proportions based on the col-
lected sample (91.4%, 5.7% and 2.9% of vials with 3, 2 and 4
patients respectively). CONCLUSIONS: The descriptive and sen-
sitivity analysis proves statistically that the MuPA is the more
time- and cost-saving and deserves to be supported.
PHP5
COST OF SEVERE BLUNT TRAUMA IN THE UK
Porter K1, Lovatt B2,Wilkinson A2
1Selly Oak Hospital, Birmingham, UK; 2Vision Health care Consultancy
Ltd, Surrey, UK
OBJECTIVE: Severe blunt trauma injuries are known to affect
more than 12,000 individuals in the UK (UK) each year, the
majority of whom require very intensive and expensive emer-
gency care. A number of studies have estimated the direct and
indirect cost of severe trauma injuries in different countries. The
objective of this study is to provide an estimate of the direct
medical cost of severe blunt trauma in the UK. METHODS: A
bottom-up costing exercise was undertaken to estimate the direct
medical cost of a typical severe blunt trauma patient involved in
a motor vehicle trafﬁc accident from the perspective of the 
UK NHS. The typical severe blunt trauma patient used in the
analysis was adapted from previously published literature to be
representative of patients presenting at UK trauma centers. UK-
speciﬁc unit costs were applied to the different items of resource
use identiﬁed in order to estimate the direct medical cost of a
severe blunt trauma patient in the UK. RESULTS: The estimated
direct medical cost of a severe blunt trauma patient in the UK is
£48,813. The main cost drivers are ICU stay (56%) and surgi-
cal intervention (32%). This estimate is similar to those reported
in the literature. The incidence of severe trauma in UK is esti-
mated to be four per one million per week (approximately
12,000 per year). This indicates that the total direct cost to the
UK NHS of severe trauma is around £0.6 billion per year. Given
that published studies suggest that the direct medical costs of
trauma represent about 25% of the total cost, the total cost of
trauma in the UK would be around 2.4 billion per year. CON-
CLUSIONS: The direct medical cost of trauma represents a sub-
stantial economic burden to society. Initiatives that reduce this
burden (e.g. prevention, treatment) are welcomed.
PHP6
DRUG PRICE INDICES 1980–2004 IN FINLAND
Hahl J1,Aaltonen S2, Linden K1, Jormanainen V1
1GlaxoSmithKline, Espoo, Finland; 2Pharma Industry Finland, Helsinki,
Finland
OBJECTIVES: To describe the development of drug wholesale
price indices in Finland in 1980–2004. METHODS: Price indices
covering study period (The Helsinki Research Institute for Busi-
ness Administration [1980–1990], IMS [1991–1994] and Statis-
tics Finland [1995–2004]) were merged into two index clusters
(1980 = 100 and 1990 = 100). The latter enables more precise
classiﬁcation according to reimbursement categories. Real price
indices were produced by adjusting nominal indices with Con-
sumer Price Index (CPI, Statistics Finland) and its sub-index
Consumer Price Index for Health Care (CPI—H, Statistics
Finland). RESULTS: In 2004, the index (1980 = 100) for all
drugs was 167 (CPI adjusted 65; CPI—H adjusted 33) and for
basic refund category 141 (55; 28), respectively. The respective
ﬁgures in 1990 = 100 index were: all drugs 107 (84; 60), pre-
scription based 101 (79; 57), reimbursed 96 (75; 54), Basic
Refund (“50%”) 96 (76; 54), Lower Special Refund (“75%”)
91 (71; 51) and Higher Special Refund (“100%”) 102 (80; 58).
CONCLUSIONS: Nominal drug wholesale prices have increased
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in Finland since 1980 and also slightly from 1990, but real prices
have constantly decreased. Depending from the adjustment index
used, the real prices of all drugs have decreased 35–67% since
1980, or 16–40% since 1990. For reimbursed drugs the devel-
opment was similar; in Basic Refund category real prices have
decreased 24–46% since 1990, and even 45–72% since 1980.
Since the effectiveness of drugs has not decreased during the time
period studied, we suggest that the cost-effectiveness of drug
treatment has clearly increased in Finland.
PHP7
MANAGING ACUTE INJURIES RESULTING FROM
MOTORCYCLE ACCIDENTS: EMERGENCY DEPARTMENT AND
INPATIENT HOSPITAL RESOURCE USE AND COSTS
O’Brien JA1, Pitoniak-Morse C1, Jacobs LM2
1Caro Research Institute, Concord, MA, USA; 2University of
Connecticut Medical School, Farmington, CT, USA
OBJECTIVES: To examine resource use and cost of Emergency
Department (ED) and hospital care for acute injuries resulting
from motorcycle accidents. METHODS: 2003 ED visit and hos-
pital discharge data from Massachusetts, where a mandatory all
age helmet law applies, were analyzed. Cases with motorcycle
accident-related injuries were identiﬁed by ICD-9 diagnosis and
external cause codes (E codes: E810.2–E825.2, E810.3–E825.3).
Inpatient cases were restricted to those admitted via ED. Type
and circumstance of injury, time of occurrence, demographics,
costs, length of stay (LOS)/visit, and disposition were examined.
Charges were adjusted by a 0.55 cost-to-charge ratio and
adjusted to national values. Cost estimates (2003US$) include
accommodations and ancillary services. RESULTS: Acute
injuries from motorcycle accidents resulted in 3066 ED visits and
420 hospitalizations during the year. Males comprised 87% of
cases; injured party was driver in 95%. Mean age was 32 years
(49% < 30 years). The majority (76%) occurred between May-
September, Friday-Sunday (52%), and 4:00 PM-midnight (54%).
Multiple injuries were noted in 44% of cases. Head injury/skull
fractures were coded for 8%. Fatalities were noted in <1% of
cases. On average, hospital LOS was 7 days (±10.1) with cost
per stay of $19,535 (±$34,688). At hospital discharge, 82%
went home (14% with home care), 17% transferred to sub-acute
facilities, 1% AMA. ED visit cost without hospitalization was
$787 (±$1,136) and was 2.7 hours (±3), on average. Manage-
ment of these injuries resulted in use of 2877 hospital days and
9274 ED visit hours at a cumulative cost of $10.5 million. CON-
CLUSIONS: This analysis shows that nearly half of the motor-
cycle accident victims sustained more than one injury; the
majority survived, and most acute injuries were managed suc-
cessfully in the ED. Although substantial, these acute care costs
are conservative estimates of injury-related costs, as they do not
include physician-related or post-acute care costs.
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RESOURCE CONSUMPTION IN PLATELET PRODUCTION
FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE
DEPARTMENT IN GERMANY
Segerer C,Wagner B,Wittmann G, Schramm W, Berger K
University Hospital of Munich, Munich, Bavaria, Germany
OBJECTIVE: Internal Cost Allocation (ICA), (e.g. Haematol-
ogy—Transfusion medicine), becomes increasingly important,
which is mainly caused by the G-DRG system. To guarantee
optimal patient care, transparency on resources, costs and ben-
eﬁts is necessary. Therefore, in a ﬁrst step resource consumption
in platelet production was assessed to calculate ﬁnally costs from
the provider’s perspective. METHODS: Prospective cost-study
(full cost pricing/process cost ﬁnding). First, main processes of
platelet production were identiﬁed. Secondly, an Excel model for
standardized data entry and calculation was developed. Data
was collected by multimeasurement-time analysis (laboratory
processes three times, other processes ten times) and material
consumption by trained staff. For cost calculations, the deter-
mined average from previous analysis was consulted. Unit cost
data were collected from internal departments, e.g. materials
logistics or personnel management. RESULTS: Platelet produc-
tion consists of ﬁve processes: preparations before and after
donation, medical examination, donation itself and laboratory
tests to detect possible infections and increase blood safety. These
require one secretary, one operator (registered nurse), four
medical-technical-assistants and two doctors. The average of
62.44 minutes per doner could be prorated to the staff as
follows: secretary 8.55%, doctor 7.7%, medical-technical-
assistant 32.63%, and operator 51.12%. At the material con-
sumption, the biggest part belonged to the laboratory reagents,
which are needed for the standard-screening consisting of 
infection-serology, polymerase-chain-reaction, blood-type deter-
mination and the determination of the remaining leucocytes.
Cost evaluation is still ongoing. CONCLUSION: Platelet pro-
duction is a time- and resource-binding process. In the context
of ICA, transparency on costs is important for budget negotia-
tions, particularly when costs and beneﬁts of the introduction of
innovations in transfusion medicine shall be evaluated. It can be
assumed that the relevance of platelet transfusions due to new
therapy approaches is growing and in consequence, product dif-
ferentiation and economic aspects are getting more important for
resource allocation in German hospitals.
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PHARMACEUTICAL CARE IN GREECE: A CITIZEN
SATISFACTION SURVEY
Geitona M1, Zavras D2, Kyriopoulos J3
1University of Thessaly, Athens, Greece; 2Hellenic Association for
Pharmacoeconomics, Athens, Greece; 3National School of Public
Health, Athens, Greece
OBJECTIVES: To evaluate user satisfaction from pharmaceuti-
cal care and determine the factors affecting it in Greece.
METHODS: A telephone survey was conducted by using a
random sample of 1000 individuals, stratiﬁed by age, county and
gender. A questionnaire was designed, containing questions
about the characteristics of the drug users, their out of pocket
spending on pharmaceuticals, the type and shape of the drug and
their satisfaction from medication. A logistic regression is done,
using as dependent variables various dimensions of satisfaction,
such as: (a) the drug effectiveness, (b) the drug shape, (c) the
health professionals’ responsiveness, (d) the appearances of side
effects and (e) the price adequacy. As independent variables
various characteristics of the respondents are used such as demo-
graphic, epidemiological and socioeconomic factors. RESULTS:
80% of Greek population is high satisﬁed from pharmaceutical
care, 91.93% from health professionals’ responsiveness, 86.03%
from the non appearances of side effects, 85.59 % from the drug
shape, 62.99 from price adequacy and 59.78% from the drug
effectiveness. Satisfaction from the drug shape, appearance of
side effects, drug effectiveness and improvement of health
depend on health status. Individuals of better health status have
a higher probability to evaluate higher their satisfaction from
medication. Satisfaction from health professionals’ responsive-
ness depends on age. Older individuals have a higher probabil-
ity to evaluate higher their satisfaction from health professionals’
responsiveness. Satisfaction from price adequacy depends on age,
social class and degree of urbanization. Lower social class older
individuals and cities residents have a lower probability to eval-
